Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.

You may also be interested in...



GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch

The anti-seizure drug should be available by the end of the year following approval June 10.

GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch

The anti-seizure drug should be available by the end of the year following approval June 10.

GSK, Valeant Willing To Exclude Some Epilepsy Patients From Potiga Market

GlaxoSmithKline and Valeant Pharmaceuticals appear willing to sacrifice a part of the target market for their anti-epileptic drug Potiga (ezogabine), as well as implement an extensive Risk Evaluation and Mitigation Strategy, in order to gain approval

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel